TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35079806
Drug: Nutrient compendium
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient compendium snacks containing ≥5 g fiber, 1000 mg ω‐3 fatty acids, 1000 mg phytosterols, and 1800 μmol antioxidants per serving.
Study: 34399585
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug classes
Study: 34399585
Drug: Lipid-lowering drug
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drug classes
Study: 34399585
Drug: Anticoagulant drug
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant drug classes
Study: 34399585
Drug: Novel drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel drug targets for inflammatory pathways
Study: 34399585
Drug: Novel drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel drug targets for coagulation cascade
Study: 33408462
Drug: Half-dose triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose triple combination (amlodipine 2.5 mg + losartan 25 mg + chlorthalidone 6.25 mg)
Study: 33408462
Drug: Third-dose triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-dose triple combination (amlodipine 1.67 mg + losartan 16.67 mg + chlorthalidone 4.17 mg)
Study: 33408462
Drug: Quarter-dose triple
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter-dose triple combination (amlodipine 1.25 mg + losartan 12.5 mg + chlorthalidone 3.13 mg)
Study: 35835521
Drug: Soft palatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft palatal augmentation prosthesis (PAP)
Study: 33745452
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (1 cc of IFABOND® applied to the surgical bed)
Study: 33008699
Drug: Three-dimensional printed
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dimensional printed ear splint therapy
Study: 35332042
Drug: Clinicians' routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinicians' routine treatment procedures
Study: 32829596
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy combined with vestibular rehabilitation training (Experimental group)
Study: 32829596
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (Control group)
Study: 32295565
Drug: Minocycline as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline as adjunctive treatment
Study: 36191986
Drug: ICIs plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICIs plus chemotherapy (chemoimmunotherapy)
Study: 36191986
Drug: ICIs plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICIs plus chemotherapy (chemoimmunotherapy) with prior brain radiotherapy
Study: 34497852
Drug: Dapagliflozin adjunct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin adjunct to continuous subcutaneous insulin infusion (CSII)
Study: 32859666
Drug: Remote support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote support for therapy programme
Study: 33060179
Drug: Identification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identification of biological motion (BM) actions by the CC group
Study: 33060179
Drug: Coherent motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coherent motion (CM) detection task by the CC group
Study: 35572961
Drug: Electro-Thumbtack Needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-Thumbtack Needle (ETN) therapy administered three times a week for four consecutive weeks
Study: 35572961
Drug: Sham ETN
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ETN therapy administered three times a week for four consecutive weeks
Study: 35572961
Drug: Electro-Thumbtack Needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-Thumbtack Needle (ETN) therapy
Study: 35572961
Drug: Sham ETN
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ETN therapy
Study: 33214593
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SAP P11‐4 and delayed FV after 90 days
Study: 35783486
Drug: Trimer 4571
Normalized name: glyoxal trimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimer 4571 adjuvanted with 500 mcg alum, administered subcutaneously or intramuscularly at weeks 0, 8, and 20 in doses of 100 mcg or 500 mcg
Study: 34237271
Drug: RO7049389 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 200 mg twice a day
Study: 34237271
Drug: RO7049389 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 400 mg twice a day
Study: 34237271
Drug: RO7049389 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 200 mg once a day
Study: 34237271
Drug: RO7049389 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 600 mg once a day
Study: 34237271
Drug: RO7049389 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 1000 mg once a day
Study: 35687059
Drug: Norepinephrine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine bolus at 0.10 μg/kg
Study: 35687059
Drug: Norepinephrine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine bolus at 0.05 μg/kg
Study: 32876804
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (2000 mg/day)
Study: 34844551
Drug: Secnidazole 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secnidazole 2.0 g po followed by Azithromycin 500 mg on day 1 continuing by 250 mg on days 2-7
Study: 34844551
Drug: Secnidazole 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secnidazole 2.0 g po followed by Josamycin 1000 mg bid for 12 days
Study: 34844551
Drug: Secnidazole 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secnidazole 2.0 g po followed by Moxifloxacin 400 mg once daily for 12 days
Study: 34047715
Drug: Home-centered activity-based
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-centered activity-based therapy (parent-supervised) in addition to institutional physiotherapy
Study: 32287316
Drug: P60.4Ac-containing ototopical
Approvals — FDA: no, EMA: no, PMDA: no
Description: P60.4Ac-containing ototopical drops (0.25-2.0 mg of peptide/ml)
Study: 32853646
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment phase
Study: 33159256
Drug: High-dose mizoribine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mizoribine (MZR) pulse therapy combined with steroid treatment
Study: 33159256
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment of steroid combined with cyclophosphamide (CPM)
Study: 33763699
Drug: Ixazomib 4
Normalized name: ixazomib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib 4 mg plus lenalidomide and dexamethasone (Rd)
Study: 34106753
Drug: Best supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care or hypomethylating therapy in the No-Donor arm
Study: 32448171
Drug: Metastasis-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metastasis-directed therapy to all visible progressive lesions
Study: 34183429
Drug: iGlarLixi (once-daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlarLixi (once-daily)
Study: 34183429
Drug: BIAsp 30
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BIAsp 30 (twice-daily)
Study: 32408108
Drug: Laxative escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative escalation criteria.
Study: 32408108
Drug: Discontinuation criteria
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation criteria for bowel protocols.
Study: 32352642
Drug: Plasma retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma retinol levels <58.3 μg/dL
Study: 32352642
Drug: Plasma retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma retinol levels ≥58.3 μg/dL
Study: 32352642
Drug: Higher time-averaged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher time-averaged SBP (≥140 mm Hg) in participants with plasma retinol <58.3 μg/dL
Study: 32352642
Drug: Higher vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher vitamin E levels (≥11.5 μg/mL) in participants with plasma retinol <58.3 μg/dL
Study: 35880280
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (balance acupotomy + warm needling)
Study: 32230987
Drug: Metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (400 mg twice daily in Week 1) followed by Inulin (4 g twice daily)
Study: 32230987
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily in Week 1) followed by Inulin
Study: 33788480
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (acupuncture, moxibustion, Chinese herbal medicine, and western medication)
Study: 33788480
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (clomiphene citrate, chorionic gonadotrophin, and aspirin)
Study: 32780258
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) received tablets with starch
Study: 36235570
Drug: BCAA (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (8 g)
Study: 36235570
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (7.5 g)
Study: 32822692
Drug: Early or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early or late prenatal vitamin D sufficiency (25(OH)D level ≥ 30 ng/mL) among mothers with asthma
Study: 32822692
Drug: Early and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early and late prenatal vitamin D sufficiency (25(OH)D level ≥ 30 ng/mL) among mothers with asthma
Study: 32822692
Drug: Early or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early or late prenatal vitamin D sufficiency (25(OH)D level ≥ 30 ng/mL)
Study: 32338067
Drug: Glycine max
Normalized name: Glycine max oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine max (L.) Merr isoflavone 4% vaginal gel
Study: 37738237
Drug: selfBACK app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: selfBACK app adjunct to usual care
Study: 34518253
Drug: e-Help website
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-Help website adjunct to usual care
Study: 35641010
Drug: Standard recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard recommended treatment regimen of chronic stable heart failure
Study: 35791797
Drug: Tegoprazan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan (50 mg) based triple therapy (TPZ)
Study: 35791797
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg) based triple therapy (LPZ)
Study: 34374027
Drug: SHR0302 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 4 mg once daily
Study: 37464978
Drug: SHR0302 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 8 mg once daily
Study: 33054769
Drug: Some anti-diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Some anti-diabetic medications
Study: 39006430
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for four weeks
Study: 35044810
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide
Study: 38479746
Drug: Oral Pre-Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Pre-Exposure Prophylaxis (PrEP)
Study: 36050704
Drug: Ketorolac injection
Normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac injection
Study: 37118707
Drug: Triamcinolone injection
Normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone injection
Study: 32694619
Drug: sHDCT/ASCT (salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: sHDCT/ASCT (salvage high-dose chemotherapy and autologous stem cell transplantation) with lenalidomide maintenance (10 mg/day) after 3 Rd reinduction cycles (lenalidomide 25 mg, day 1–21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles)
Study: 38305378
Drug: Vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (125 mg 4 times daily for 10 days)
Study: 32571567
Drug: Uninterrupted (or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted (or minimally interrupted) direct oral anticoagulants (DOACs)
Study: 32571567
Drug: Continuous vitamin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous vitamin K antagonists
Study: 32482433
Drug: Therapeutic exercise
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic exercise (TE) program in combination with the integrated neuromuscular inhibition technique (INIT)
Study: 33168234
Drug: Optimized delayed-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized delayed-release and extended-release methylphenidate (DR/ER‐MPH)
Study: 33576545
Drug: Oxycodone/Acetaminophen
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone/Acetaminophen
Study: 35013131
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (50 mg)
Study: 35058090
Drug: Intraoperative injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative injection of 10 ml (133 mg) liposomal bupivacaine
Study: 32681303
Drug: Aerobic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic and resistance exercise intervention (supervised, moderate-vigorous, thrice weekly for 16 weeks)
Study: 32703288
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT)‐based depression prevention
Study: 36432607
Drug: 8 mg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg·kg bw−1 of caffeine (CF8)
Study: 35460400
Drug: Estrogen valerate
Normalized name: valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen valerate pretreatment (2 mg twice a day from Day 7 after ovulation to Day 2 of the next menstrual cycle)
Study: 34663095
Drug: Concurrent partner
Normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent partner treatment with oral metronidazole (400 mg) and 2% clindamycin cream applied topically to penile skin, both twice daily for 7 days.
Study: 34663095
Drug: Concurrent partner
Normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent partner treatment
Study: 32250461
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of antidepressants (overall)
Study: 33506929
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (L. rhamnosus GG) administered postoperatively for 30 days
Study: 33891478
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (5 weekly cycles of carboplatin and paclitaxel with concurrent radiotherapy at 41.4 Gy in 23 fractions, 5 days per week) followed by surgery
Study: 32936533
Drug: Test metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test metformin hydrochloride tablet (0.25 g)
Study: 32936533
Drug: Reference metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference metformin hydrochloride tablet (0.25 g)
Study: 36440744
Drug: Action observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action observation therapy
Study: 36440744
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy and action observation
Study: 32294394
Drug: Greek yogurt
Normalized name: Greek pitch
DrugBank: Rosin (DB11165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greek yogurt with granola (150 kcal, 9.2 g protein, 2.6 g fat, 2.0 g dietary fibre, and 21.5 g available carbohydrate/100 g)
Study: 32294394
Drug: Cultured coconut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultured coconut product with granola (146 kcal, 3.2 g protein, 3.2 g fat, 5.6 g dietary fibre, and 21.9 g available carbohydrate/100 g)
Study: 36038984
Drug: EHA cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EHA cream (1% ectoine and 0.1% hyaluronic acid), applied twice daily for 4 weeks
Study: 36038984
Drug: Vehicle cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream, applied twice daily for 4 weeks
Study: 36038984
Drug: EHA cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EHA cream (1% ectoine and 0.1% hyaluronic acid)
Study: 36038984
Drug: EHA cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EHA cream
Study: 32672654
Drug: Scleral patch
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scleral patch graft (SPG) technique
Study: 36401133
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus chemotherapy (NIVO + Chemo)
Study: 33058746
Drug: Complex decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex decongestive therapy (CDT) including manual lymphatic drainage (MLD) before bandaging, 15 sessions over 3 weeks.
Study: 33058746
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ST) including compressive multilayer bandaging and exercise training, 15 sessions over 3 weeks.
Study: 32742443
Drug: Sequential chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoradiotherapy
Study: 34344672
Drug: HCQ 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ 200 mg/day + BHH 8 mg/8 hours
Study: 35765728
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 0.3% ropivacaine
Study: 35765728
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 0.3% ropivacaine
Study: 33242998
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with U-500R
Study: 33242998
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection (SC) of U-500R
Study: 32086599
Drug: CHO‐L (carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐L (carbohydrate loaded)
Study: 34678198
Drug: Capsular group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsular group A meningococcal conjugate vaccine (MenA)
Study: 35410189
Drug: Monthly Clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly Clinical Supervision for up to two years
Study: 33753657
Drug: Sealants placed
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealants placed with bonding agent
Study: 33753657
Drug: Sealants placed
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealants placed without bonding agent
Study: 35899211
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical minoxidil (MX) alone, once daily
Study: 35899211
Drug: Minoxidil plus
Normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minoxidil plus oral spironolactone (SPT) 80–100 mg daily
Study: 33115487
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (manual therapy)
Study: 33217416
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume mechanical ventilation (3 mL/kg 5 times/min, with positive end expiratory pressure of 5 cm H2O) during CPB
Study: 33034145
Drug: Piroxicam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (single dose 1–2 hours before frozen-thawed ET)
Study: 33034145
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered at the same time as piroxicam)
Study: 32503502
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral composition
Study: 35110393
Drug: CVN424 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVN424 (1 mg to 225 mg single doses; 25, 75, or 150 mg repeated daily doses for 7 days)
Study: 35110393
Drug: CVN424 (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVN424 (dosing after a standardized high-fat meal)
Study: 35110393
Drug: CVN424 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVN424 (various doses)
Study: 33038007
Drug: Topical niacinamide
Normalized name: niacinamide Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical niacinamide
Study: 35568312
Drug: Active HD-tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active HD-tDCS (twice a day, 30-min, 3-mA) plus respiratory rehabilitation
Study: 33855355
Drug: Intermittent two-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent two-drug regimens (2-DRs) given 4-5 days a week
Study: 33855355
Drug: Intermittent two-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent two-drug regimens (2-DRs)
Study: 36260786
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with 5-fluorouracil and folinic acid or capecitabine plus oxaliplatin (FOLFOX6 or CAPEOX; Arm 1)